Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibodyAdrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity...
Adrenomed AG is a privately-financed, clinical-stage biopharmaceutical company with a clear mission: to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. The Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibodyAdrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity to treat life-threatening conditions associated with increased vascular leakage, congestion and shock.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.